Sanofi could get up to €300m ($329.5m) from Blackstone Life Sciences to advance a subcutaneous formulation of Sarclisa in the hopes of measuring up to Johnson & Johnson andvGenmab A/S’s formidable competitor Darzalex.
Under a new “strategic risk-sharing collaboration,” private equity giant Blackstone would contribute the cash to help accelerate global pivotal studies...








